Abstract
Background: Topical efinaconazole (EFN) shows mycologic cure (MC) of 53%-55%, complete cure (CC) of 15%-18%, and few EFN-related reactions (1.2%-5.5%) following 12-month use in patients 18-70 yrs with mild-moderate onychomycosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
